引言激素受体阳性（HR+）/人表皮生长因子受体 2 阴性（HER2-）乳腺癌是最常见的乳腺癌亚型，约占所有乳腺癌的 70%。近年来，细胞周期蛋白依赖性激酶 4/6（CDK4/6）抑制剂联合内分泌治疗已成为 HR+/HER2- 晚期乳腺癌的一线标准治疗 ...

Drs Ursula A. Matulonis and Panagiotis A. Konstantinopoulos discuss hormonal therapy updates and different ways to target and ...

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

CDK4/6 inhibitor plus endocrine therapy is an active treatment option for premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer compared with chemotherapy ...

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

Health insurers no longer completely cover two breast cancer drugs for women with metastasised hormone receptive breast ...

Ignite Proteomics offers the only commercially available and clinically validated assay that measures both the expression and activation levels of drug targets in breast tumors. This innovative ...